Stay updated on Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial
Sign up to get notified when there's something new on the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page.

Latest updates to the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page
- Check5 days agoChange DetectedGlossary toggle is now shown on the page. Minor textual updates include capitalization changes for 'Last Update Submitted' and 'No FEAR Act data', and a new revision label v3.4.0.SummaryDifference0.2%

- Check12 days agoChange DetectedSponsor field updated from FibroGen to Kyntra Bio. FibroGen is no longer listed as sponsor.SummaryDifference0.3%

- Check19 days agoChange DetectedThe page now displays Revision: v3.3.4 added and Revision: v3.3.3 removed, indicating a minor internal version update. This change does not affect study details, eligibility criteria, or how a user interacts with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedNew Locations section added listing participating sites by state (Arizona, California, District of Columbia, Florida, Louisiana, Minnesota, Pennsylvania, Washington). The HHS Vulnerability Disclosure footer link was removed.SummaryDifference0.9%

- Check70 days agoChange DetectedFooter revision text updated from Revision: v3.2.0 to Revision: v3.3.2; overall page content and layout remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check77 days agoChange DetectedThe page removed a generic government funding status notice; this is a non-critical change that does not affect the study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gemcitabine/Nab-paclitaxel ± FG-3019 Clinical Trial page.